UGT1A1*28基因多态性与伊立替康治疗晚期非小细胞肺癌的毒副反应及疗效的关系研究

The Association of UGT1A1* 28 Polymorphism with the Efficacy and Toxicity of Irinotecan Chemotherapy in Non-small Cell Lung Cancer

目的探讨UGT1A1*28基因多态性与CPT-11治疗晚期NSCLC的毒副反应与疗效的关系。方法外周血检测2015年6月至2016年6月在九江市第一人民医院所收治的50例晚期NSCLC患者UGTIA1*28 TATA盒基因序列,并对所有50例患者接受CPT-11为基础化疗方案的患者出现的不良反应和近期疗效随访记录,比较不同基因型之间的差别。结果 50例晚期NSCLC患者中UGTIA1*28位点突变型可以增加发生3级以上腹泻(P=0.007)和3级以上血小板减少(41.7%VS 10.5%,P=0.027)的风险。结论在CPT-11化疗的患者中,UGTl Al*28基因型TA6/7,或TA7/7基因型可增加晚期NSCLC患者发生Ⅲ度以上腹泻及血小板减少的风险,然而不影响化疗的近期疗效。

Objective To explore the realtionship UGT1A1 ＊ 28 gene polymorphisms and irinotecan - associated toxicity and efficacy in treatment of non - small cell lung cancer. Methods The frequency of UGT1A1 ＊28 TATA box thymine - adenine （TA） was performed by direct sequencing. The influence of the UGT1A1 ＊ 28 polymorphism on the short - term efficacy and toxicity of irinotecan was record. Results Among 50 patients with non - small lung cancer, marked increases in diarrhea （ 58.3% VS 15.8%, P = 0.007） and thrombocytopenia （ 41.7% VS 10.5%, P = 0.027） were observed in patients who had the TA6/7 or T7/7 genotype. Conclusion This study demonstated that UGT1A1 ＊28 polymorphism TA6/7 or T7/7 increased the risk the developing grade IH or more sever diarrhea and thrombocytopenia for patients after receiving irinotean treatment but no influence on short - term efficacy of chemotherapy.